Name: Regencell Bioscience Holdings Limited (RGC) Financial Statements
Creator: FinSpry

Regencell Bioscience Holdings Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Regencell Bioscience Holdings Limited income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	0.39	0.00	0.00	0.00	0.00
Gross Profit	-0.39	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	0.95	1.07	1.58	2.51	0.44
Selling, General & Administrative	2.43	3.67	4.69	5.11	0.94
Operating Expenses	3.38	4.74	6.27	7.62	1.38
Operating Income	-3.77	-4.74	-6.27	-7.62	-1.38
Other Income/Expense
Interest Income	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	0.19	0.37	0.21	0.02	0.03
Income
Income Before Tax	-3.58	-4.36	-6.06	-7.59	-1.35
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-3.58	-4.30	-5.87	-7.45	-1.35
Net Income - Continuous Operations	-3.58	-4.36	-6.06	-7.59	-1.35
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-3.19	-3.99	-5.50	-7.47	-1.35
EBIT	-3.77	-4.74	-6.27	-7.62	-1.38
Depreciation & Amortization	0.39	0.75	0.77	0.15	0.03
Earnings Per Share
Basic EPS	-	-	-	-	-
Diluted EPS	-	-	-	-	-
Basic Shares Outstanding	494.49	494.49	494.49	486.62	480.40
Diluted Shares Outstanding	494.49	494.49	494.49	486.62	480.40